此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 (ACT-REACT)

2026年6月29日 更新者:Dr. Bijoy Menon、University of Calgary

A Multicentre,Prospective,Randomized,Open Label,Blinded-endpoint Trial for Reperfusion Enhancement After Completing Thrombectomy Using Intraarterial Thrombolysis(REACT-IA-Thrombolysis Domain)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke(ACT-GLOBAL) NCT06352632

Study Design and Duration:

This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 subjects with Acute Ischemic Stroke (AIS) who undergo EVT. Randomisation will be stratified by country/ region, and the IA thrombolytic agent (tenecteplase or alteplase). Minimal sufficient balance algorithm will operate within each stratum to preserve balance on key covariates while maintaining allocation randomness.

Participants will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. Primary outcome data will be determined by simplified, structured method of assessment using the modified Rankin scale (mRS), conducted through centralized telephone interviews or online media performed by central trial personnel blinded to treatment assignment and received.

Domain Interventions:

The intervention group will receive a single dose of local intraarterial thrombolysis using either tenecteplase (at a dose of 0.0625mg/kg; maximum dose of 6.25mg) or alteplase (0.225 mg/kg; maximum dose, 20mg) at the end of EVT procedure plus standard of care while the control group will receive standard of care alone. The selection of the thrombolytic agent will be determined according to local availability. The dose of intraarterial thrombolysis will be increased if the above dose meets prespecified posterior probabilities at the first or second interims.

In all eligible patients:

  1. Local intra-arterial thrombolysis using either tenecteplase at a dose of 0.0625mg/kg "maximum dose of 6.25mg" or alteplase "0.225 mg/kg; maximum dose, 20mg*
  2. No intra-arterial thrombolysis.

    • The dose of IA thrombolysis may be doubled to 0.125 mg/kg tenecteplase or 0.45 mg/kg alteplase if this dose shows futility at pre-specified interims Randomization will be stratified by country/ region, the IA thrombolytic agent used (tenecteplase or alteplase). IA thrombolysis will be administered as a one-time treatment.

研究概览

详细说明

This is a domain within the ACT-GLOBAL platform trial to compare IA thrombolysis use (Yes vs No) following the completion of endovascular thrombectomy procedures among subjects who did not receive IV thrombolysis.

The key arguments for the proposed trial are:

  • About 50% of patients treated with EVT are left with distal occlusions that cannot be reached with current devices. Even when reperfusion is considered complete, evidence suggests microthrombi persist in downstream cerebral circulation, contributing to poor outcomes.
  • Other approved acute stroke treatments such as intravenous thrombolysis or antithrombotics do not address incomplete reperfusion. Approximately half of stroke patients treated with EVT are not concurrently or pre-treated with IV thrombolysis.
  • Systemic antithrombotics used in conjunction with IV thrombolysis are unsafe or ineffective.
  • Prospective cohorts and randomized controlled trials (RCTs) suggest that targeted intraarterial thrombolysis offered directly to the affected arterial territory is a promising approach to enhance reperfusion when thrombectomy with mechanical devices is complete. Recent meta-analyses from small pilot studies suggest safety of this approach.
  • Recent RCTs showed mixed results but with overall potentially better clinical outcomes with intraarterial thrombolysis using either tenecteplase or alteplase.
  • A high quality, large, pragmatic, and globally representative confirmatory trial is needed to generate definitive evidence and inform clinical practice on the safety and benefit of IA thrombolysis.

Modern endovascular thrombectomy (EVT) offered using mechanical devices like stent-retrievers and aspiration catheters has revolutionized acute stroke therapy and improved outcomes. Still, a significant gap exists between EVT procedural success and clinical recovery in patients with large vessel occlusion stroke. Less than half of patients receiving EVT achieve functional independence (modified Rankin Scale "mRS" 0-2) despite medical care and rehabilitation. Moreover, ~15% of all EVT procedures fail with subsequent dismal outcomes. Incomplete reperfusion is a major reason that explains why many patients fail to recover fully after thrombectomy. This phenomenon occurs either because of clot fragments that lodge in distal arteries (micro-embolization), or because of in-situ thrombus formation in the micro-circulation. These occlusions are too distal for current devices to reach. However, they can be reached in a targeted manner by administering chemical thrombolysis directly into target areas through catheters lodged in large arteries.

While the incidence and consequences of macrocirculatory obstruction are well-described, microcirculatory obstruction (also called no-reflow) has not been extensively studied in stroke. Nonetheless, it has been reported in 25% of patients post successful EVT with associated higher odds of infarct growth, and poor functional outcomes including death. In an imaging sub study of the CHOICE phase II RCT (comparing local intraarterial "IA" alteplase vs placebo following successful thrombectomy), 58% of patients enrolled to the control arm demonstrated persistent hypoperfusion on MRI at 48 hours after successful EVT. This hypoperfusion was postulated to result from microcirculatory obstruction and was associated with poor outcomes.

Intravenous thrombolysis given prior to EVT may have some effect on lysing downstream thrombi once endovascular recanalization is achieved. However, around half of EVT-treated patients do not receive IV thrombolysis due to contraindications or presenting outside IV thrombolysis treatment window. In addition, the short half-life of IV thrombolytic agents (plasma elimination half-life of ~ 3.5 minutes for alteplase and ~20 minutes for tenecteplase) means that they may not have any effect on thrombi that persist after EVT is completed. In a study of 1303 patients from the German stroke registry, patients in whom the IV alteplase infusion was still ongoing at the end of EVT had higher odds of achieving excellent recovery compared to those who completed the infusion prior to EVT completion. Recent RCTs exploring antithrombotics agents to enhance reperfusion either showed harm (IV ASA ( acetylsalicylic acid) with or without IV heparin) or lack of benefit (IV tirofiban).

Targeted intra-arterial (IA) thrombolysis is a promising adjunct therapy that can be offered to enhance reperfusion immediately after EVT. Thrombolysis administered directly in the affected vascular bed maximizes the fibrinolytic effect on the local cerebral circulation while reducing systemic uptake and side effects. Different thrombolytic agents have been used for IA stroke therapy. However, meta-analyses suggest low quality evidence of available studies given their observational nature and restrictive selection criteria. In one meta-analysis of five observational studies (n=269 patients), there was a suggestion of better functional independence with intraarterial alteplase or urokinase over controls (OR: 1.34; 95% CI: 1.00 to 1.80) without increased risk of symptomatic hemorrhage or death. In the INFINITY registry conducted in 10 European centers, IA alteplase was associated with improved reperfusion in 50% of patients who achieved incomplete reperfusion after EVT. The phase II RCT (CHOICE, n=121 subjects) of IA alteplase after successful EVT at a dose equivalent to 25% of the maximum IV alteplase dosing showed the safety and efficacy of this approach. This trial was stopped prematurely due to placebo supply constraints. Still, it showed an absolute risk difference of 18.4% (95%CI 0.3%-36.4%; P=0.047) in excellent outcome (mRS 0-1) favouring IA alteplase, without increased risk of symptomatic intracranial haemorrhage. In an imaging sub study of the trial, 58% of patients enrolled to the control arm demonstrated persistent hypoperfusion on MRI despite angiographically successful EVT. These results need to be interpreted with caution however given small sample size and premature closure of study. A phase III RCT (PEARL, n=324 subjects) with a similar design and IA alteplase dosing as CHOICE was presented recently (unpublished) and showed improved mRS 0-1 in the treatment arm compared to controls with an absolute risk difference of 15% (95%CI 3.7%-26.3%; P=0.01).

Tenecteplase is a promising agent for IA thrombolysis. It has superior pharmacokinetic properties over alteplase including its longer half-life (~20 minutes), and greater fibrin specificity. Our large CIHR (Canadian Institute of Health Research) funded AcT (Alteplase compared to Tenecteplase) RCT (n=1600 subjects) demonstrated the non-inferiority and comparable safety of IV tenecteplase (0.25 mg/kg) vs. alteplase for all ischemic stroke patients eligible for IV thrombolysis. In 520 patients treated with EVT in AcT, there was a suggestion of better recanalization with tenecteplase and similar safety. The EXTENDIA-TNK trial showed superior recanalization and better outcomes among patients treated with IV tenecteplase vs those treated with IV alteplase. Therefore, tenecteplase is now the standard for IV thrombolysis in acute ischemic stroke. The current Canadian Best Practice guidelines recommend tenecteplase as an alternative to alteplase in all eligible stroke patients. Tenecteplase can be administered intraarterially and may help reperfuse the brain better than but as safe as IA alteplase. While two prior RCTs using IA tenecteplase in patients with anterior circulation (POST-TNK, n=540 subjects), and posterior circulation (ATTENTION, N=208 subjects) strokes following endovascular reperfusion showed neutral results, a recent phase III RCT of IA tenecteplase in anterior circulation stroke patients following endovascular reperfusion showed positive results. The ANGEL-TNK trial (n= 255 subjects) was recently presented and showed that patients treated with IA tenecteplase at a dose equivalent to 50% of the IV tenecteplase dose had better 90-day mRS 0-1 compared to controls (40.5% vs 26.4%, OR 1.4, 95%CI 1.1 to 2) without safety concerns.

While these results suggest a potential benefit of IA thrombolysis following thrombectomy, the heterogeneity of existing trials, their narrow geographic scope (conducted primarily in China or Spain), and the inconsistent benefit across key functional outcomes (e.g., improvement in mRS 0-1 but not mRS 0-2 or ordinal shift) underscore the necessity for a globally representative, large-scale, pragmatic confirmatory trial to provide definitive evidence and guide clinical practice.

Domain Rationale:

The key arguments for the proposed trial are:

  • About 50% of patients treated with EVT are left with distal occlusions that cannot be reached with current devices. Even when reperfusion is considered complete, evidence suggests microthrombi persist in downstream cerebral circulation, contributing to poor outcomes.
  • Other approved acute stroke treatments such as intravenous thrombolysis or antithrombotics do not address incomplete reperfusion. Approximately half of stroke patients treated with EVT are not concurrently or pre-treated with IV thrombolysis.
  • Systemic antithrombotics used in conjunction with IV thrombolysis are unsafe or ineffective.
  • Prospective cohorts and randomized controlled trials (RCTs) suggest that targeted intraarterial thrombolysis offered directly to the affected arterial territory is a promising approach to enhance reperfusion when thrombectomy with mechanical devices is complete. Recent meta-analyses suggest safety of this approach.
  • Recent RCTs showed mixed results but with overall potentially better clinical outcomes with intraarterial thrombolysis using either tenecteplase or alteplase. The combination of IV thrombolysis plus IA thrombolysis did not result in safety concerns.
  • A high quality, large, pragmatic, and globally representative confirmatory trial is needed to generate definitive evidence and inform clinical practice on the safety and benefit of IA thrombolysis.

DOMAIN AIMS AND OBJECTIVES

This domain aim is to efficiently, reliably, and simultaneously, determine the effectiveness of targeted intraarterial (IA) thrombolysis using either tenecteplase at a dose of 0.0625mg/kg (maximum dose of 6.25mg) or alteplase (0.225 mg/kg; maximum dose, 20mg) vs. no IA thrombolysis in all patients who undergo EVT. For participants allocated to the IA thrombolysis arm, the selection of thrombolytic agent (tenecteplase or alteplase) will be determined according to local availability.

This domain of the ACT-GLOBAL platform is designed in such a way that the accrued data could be used to design and then ask a future research question on IA thrombolysis in a pertinent subgroup of patients

研究类型

介入性

注册 (估计的)

1500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N2T9
      • Edmonton、Alberta、加拿大
        • University of Alberta
        • 首席研究员:
          • Brian Buck, MD
        • 接触:
    • British Columbia
      • Kelowna、British Columbia、加拿大
        • Kelowna Regional Hospital
        • 首席研究员:
          • Aleksander Tkach, MD
      • New Westminster、British Columbia、加拿大
        • Royal Columbian Hospital
        • 首席研究员:
          • George Medvedev, MD
        • 接触:
          • Vishaya Naidoo
      • Vancouver、British Columbia、加拿大
    • Manitoba
      • Winnipeg、Manitoba、加拿大
        • University of Manitoba - Winnipeg Health Science Centre
        • 首席研究员:
          • Nishita Singh, MD
        • 接触:
    • Ontario
      • Greater Sudbury、Ontario、加拿大
        • Health Sciences North Horizon Sante-Nord
      • Ottawa、Ontario、加拿大
        • Ottawa Civic Hospital
        • 首席研究员:
          • Dariush Dowlatshahi, MD
        • 接触:
      • Toronto、Ontario、加拿大
        • Sunnybrook Health Science Centre
        • 首席研究员:
          • Richard Swartz, MD
        • 接触:
    • Quebec
    • Saskatchewan
      • Saskatoon、Saskatchewan、加拿大
        • Royal University Hospital
    • Barangaroo
      • Sydney、Barangaroo、澳大利亚、NSW 2000
        • The George Institute for Global Health
        • 首席研究员:
          • Craig Anderson, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Age ≥18 years
  2. Clinical diagnosis of stroke

Exclusion Criteria:

There are no platform level exclusion criteria.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Local intra-arterial (IA) thrombolysis using either tenecteplase or alteplase
The intervention group will receive local intra-arterial (IA) thrombolysis using either tenecteplase at a dose of 0.0625mg/kg "maximum dose of 6.25mg" or alteplase "0.225 mg/kg; maximum dose, 20mg.
Intra-arterial thrombolysis after endovascular therapy
其他名称:
  • Thrombolytic (2 options)
  • tNKase, Metalyse,
  • tPA, Activase
安慰剂比较:No IA thrombolysis
No intra-arterial thrombolysis.
No intra-arterial thrombolysis after endovascular therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
在修改后的Rankin量表(mRS)上评估的整个结果分布中分析功能依赖性的减少,
大体时间:从注册到第 90 天评估 - 第 90 天结果以盲法评估
改良兰金量表 (mRS) - 0 到 1 分表示无症状或有症状但无残疾的良好结果,2 到 5 分表示残疾(和依赖性)程度增加,6 分表示死亡。
从注册到第 90 天评估 - 第 90 天结果以盲法评估

次要结果测量

结果测量
措施说明
大体时间
Rate of 90-day mortality
大体时间:From enrollment to the Day 90 assessment.
Date and cause of death are collected from randomization until End of Study.
From enrollment to the Day 90 assessment.

其他结果措施

结果测量
措施说明
大体时间
The Proportion of participants with a Modified Rankin Scale (mRS) of 0-1 at Day 90.
大体时间:Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.
Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
The Proportion of participants with a Modified Rankin Scale (mRS) of 0-2 at Day 90.
大体时间:Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome
Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
Rating the Health-related quality of life, as measured by the EQ-5D-5L at Day 90.
大体时间:Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
The EQ-5D-5L is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems. The version of the instrument selected for the trial is interviewer administered either in-person, or by telemedicine or by telephone. The respondents will also rate their overall health on the day of the interview on a 0-100 visual analogue scale (EQ-VAS).
Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
Safety Assessments of Serious Adverse Events (SAEs) from enrollment up to Day 4
大体时间:From enrollment ( randomization) to the Day 4
Serious Adverse events include the following events :results in death, life threatening,Requires inpatient hospitalization or prolongation of existing hospitalization,Results in persistent disability/incapacity,Is a congenital anomaly/birth defect, an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the participant and may require medical or surgical intervention to prevent an outcome listed in the SAE selection.
From enrollment ( randomization) to the Day 4
The proportion of patients with Symptomatic intracranial hemorrhage from enrolment up to Day 4
大体时间:From enrollment ( randomization) to the Day 4
Any new intracranial hemorrhage detected by brain imaging associated with neurological worsening or deterioration of symptoms.
From enrollment ( randomization) to the Day 4
The proportion of patients with large parenchymal hemorrhage (PH-2) from enrolment up to Day 4
大体时间:From enrollment ( randomization) to the Day 4
PH-2:( hemorrhage grading scale) homogeneous hyperdensity occupying over 30% of the infarct zone, with significant mass effect
From enrollment ( randomization) to the Day 4
The Ordinal shift of 7 levels of mRS at 90 days
大体时间:Done by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.
Done by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)
The Proportion of participants achieving first pass (eTICI 2c or higher) reperfusion (when treated with EVT).
大体时间:Completed by the Central Core lab at 30 days after randomization
The thrombolysis in cerebral infarction (TICI) grading system as a tool for determining the response of thrombolytic therapy for ischemic stroke. In neurointerventional radiology it is commonly used for patients post endovascular revascularization.
Completed by the Central Core lab at 30 days after randomization
The Proportion of participants achieving successful recanalization (revised arterial occlusive lesion [rAOL] score of 2b-3) at first angiographic acquisition (when treated with EVT).
大体时间:Completed by the Central Core lab at 30 days after randomization
The thrombolysis in cerebral infarction (TICI) grading system as a tool for determining the response of thrombolytic therapy for ischemic stroke. In neurointerventional radiology it is commonly used for patients post endovascular revascularization.
Completed by the Central Core lab at 30 days after randomization
The Ambulatory status at discharge
大体时间:Completed at Day 4.
Assessing mobility of the patient at discharge
Completed at Day 4.
The Place of residence at 90 days
大体时间:Completed at the Day 90 assessment.
Assessing the patient's residence at the Day 90 follow up. ( example: home,rehabilitation, long term care, remains hospitalized)
Completed at the Day 90 assessment.
Imaging assessment of infarct size and edema volume
大体时间:Completed by the Central Core lab at 30 days after randomization
The total absolute infarct volume is the sum of infarct volumes calculated for each slice.
Completed by the Central Core lab at 30 days after randomization
Summative total length of hospital stay in the first 90-days after stroke onset
大体时间:Completed at the Day 90 assessment.
Calculating the total number of days the patient was hospitalized since their hospital admission.
Completed at the Day 90 assessment.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Bijoy K Menon, MD、University Of Calgary
  • 首席研究员:Craig Anderson, MD、The George Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月10日

初级完成 (估计的)

2030年12月31日

研究完成 (估计的)

2031年3月31日

研究注册日期

首次提交

2025年9月11日

首先提交符合 QC 标准的

2026年6月29日

首次发布 (实际的)

2026年7月7日

研究记录更新

最后更新发布 (实际的)

2026年7月7日

上次提交的符合 QC 标准的更新

2026年6月29日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Domain information and tabular trial results will be posted on the National Institutes of Health's website www.clinicaltrials.gov within one year of domain completion.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅